Technology
Health
Pharmaceutical

Amneal Pharmaceuticals

$14.05
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.48 (-3.30%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell AMRX and other stocks, options, ETFs, and crypto commission-free!

About

Amneal Pharmaceuticals, Inc. Class A Common Stock, also called Amneal Pharmaceuticals, is a pharmaceutical company, which engages in the development, manufacture, market and distribution of generic pharmaceutical products. Read More It operates through the Generics and Specialty segments. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermals. The Specialty segment provides proprietary medicines to the U.S. market. The company was founded by Chintu Patel and Chirag Patel in 2002 and is headquartered in Bridgewater, NJ.

Employees
6,000
Headquarters
Bridgewater, New Jersey
Founded
2002
Market Cap
1.85B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
1.20M
High Today
$14.41
Low Today
$13.88
Open Price
$14.41
Volume
220.69K
52 Week High
$24.48
52 Week Low
$11.63

Collections

Technology
Health
Pharmaceutical
2018 IPO
US
North America

News

Guru FocusMar 12

Amneal Pharmaceuticals Inc (AMRX) President and CEO Robert A Stewart Bought $202,640 of Shares

President and CEO of Amneal Pharmaceuticals Inc (NYSE:AMRX) Robert A Stewart bought 17,000 shares of AMRX on 03/12/2019 at an average price of $11.92 a share.

316
PR NewswireMar 12

Amneal Announces Launch of Rivastigmine Transdermal System

BRIDGEWATER, N.J., March 12, 2019 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX), today announced that it has launched its generic version of Exelon® Patch (Rivastigmine Transdermal System), 4.6 mg/24 hours, 9.5 mg/24 hours, and 13.3 mg/24 hours. The Company received FDA approval of its Rivastigmine Transdermal System in January 2019, and has received final approval on 10 Abbreviated New Drug Applications this year. "We are pleased to have received approval on and launched the company's first tr...

29
PR NewswireMar 6

Amneal Pharmaceuticals to Present at the Barclays Global Healthcare Conference

BRIDGEWATER, N.J., March 6, 2019 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that members of management will participate in a fireside chat at the Barclays Global Healthcare Conference at the Loews Miami Beach Hotel in Miami on Wednesday, March 13, 2019. To access a live webcast of the presentation, visit Amneal's Investor Relations Web site at https://investors.amneal.com. The webcast can also be accessed at the following URL: https://cc.talkpoint.com/barc002/031219a_as/?enti...

74

Earnings

$0.22
$0.26
$0.29
$0.33
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Available May 9, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.